News Feed Item

Bullish Trend Analysis Report: Petroleo Brasileiro Petrobras, XOMA Corp, Groupon Inc, EnteroMedics Inc, Schlumberger Limited

NEW YORK, December 4, 2013 /PRNewswire/ --

Market Buzz Report, an online penny stock community, issues stock analysis for Petroleo Brasileiro Petrobras SA (NYSE:PBR), XOMA Corp (NASDAQ:XOMA), Groupon Inc (NASDAQ:GRPN), EnteroMedics Inc (NASDAQ:ETRM), Schlumberger Limited (NYSE:SLB).

Petroleo Brasileiro Petrobras SA (NYSE:PBR) plunged 11% after Friday's announcement of a 4% price rise for gasoline and 8% for diesel, but "for commercial reasons, the parameters of the pricing methodology will be strictly internal to Petrobras." Raymond James analysts also say the guidelines on the pricing methodology are confusing, with two seemingly contradictory objectives: The first is to "reach, in a compatible time period, the alignment between Brazilian and international prices," while the second is to "prevent transferring the volatility of international prices to the domestic consumer."

Free Urgent Insider Catalyst Report For PBR Available Here:  (Or Copy and paste the URL into your browser)

Analysts weigh in very negatively on Petrobras timid fuel price increases and opaque pricing methodology. Credit Suisse downgrades shares all the way to Sell from Buy, citing a lack of management credibility and the lack of a business friendly government in Brazil after Friday's announcement. PBR wants to reduce its debt burden to below 2.5x net debt to EBITDA but for that to happen, Credit Suisse notes it must raise its fuel price by 20% in 2015, which has not been done before. The market is concerned that this could be the last price increase until the 2014 presidential election, Deutsche Bank adds.

XOMA Corp(NASDAQ:XOMA) could be in for a big post-Thanksgiving move today based on news that the biotech-focused hedge fund Baker Brothers has been snapping up the company's shares as of late. Specifically, the fund now owns more than $100 million in XOMA, and their optimism has paid off handsomely so far this year. Based on the positive clinical development of the company's lead antibody gevokizumab in a wide variety of inflammatory conditions, XOMA shares have nearly doubled year to date.

Free Urgent Insider Catalyst Report For XOMA Available Here:  (Or Copy and paste the URL into your browser)

Although this rise has certainly been impressive, the best may be yet to come. A few weeks ago, XOMA announced compelling proof-of-concept data from two different studies for gevokizumab. During the initial data release, XOMA said it'll move forward with plans to conduct a late-stage trial for gevokizumab as a treatment for pyoderma gangrenosum, a rare type of skin ulcer. And recently, XOMA decided to go forward with a second late-stage trial to study the antibody in erosive osteoarthritis of the hand.

Groupon Inc (NASDAQ:GRPN) reports its North American billings for the four-day Thanksgiving weekend were up 30% Y/Y.  The company adds 55% of those transactions took place via mobile devices. (PR) The billings growth rate is soundly above the 20% North American gross billings growth Groupon reported for Q3, and even with the 30% clip it reported for Q2. The share of N.A. transactions coming via mobile appears to be up slightly from Q3, during which time mobile accounted for "over 50%" of buying activity. Amazon and eBay also saw strong weekend sales.

Free Urgent Insider Catalyst Report For GRPN Available Here:  (Or Copy and paste the URL into your browser)

Shares of EnteroMedics Inc(NASDAQ:ETRM) were holding onto this morning's big gains - and then some.

Count Northland Capital's Suraj Kalia among those who think the stock has further to run. "Based on the current 18-month data, and barring any unforeseen kinks in any subgroup analysis (only top-line data has been released so far), we do not envision a mixed or negative ruling in an FDA panel," Kalia says, referencing the pivotal VBLOC study.

Northland's target is $7 and although Kalia says that the firm "can articulate on DCF's as to how [the] price target was achieved ... ETRM could now be a good takeout target post-approval."

Free Urgent Insider Catalyst Report For ETRM Available Here:  (Or Copy and paste the URL into your browser)

Schlumberger Limited (NYSE:SLB) says it expects the temporary shutdown of its operations in southern Iraq last month in a security incident to reduce Q4 profits ~2%, impacting EPS $0.02-$0.03; the average analyst earnings estimate for the quarter is $1.37/share. SLB says activity has nearly returned to normal at the location, and expects continued strong growth in Iraq next year, SLB's president of operations and integration tells an investor conference. Otherwise, SLB reiterates expectations for spending growth in 2014, particularly in the Gulf of Mexico, sub-Saharan Africa, Russia, the Middle East and China.

Free Urgent Insider Catalyst Report For SLB Available Here:  (Or Copy and paste the URL into your browser) is an investment community that Focuses on MicroCap Securities. is an  authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at Follow us on Facebook: Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126.  (SMS alerts are free, however data rates may apply, check your wireless plan for details.)

DISCLAIMER:  FNNewswire (FNNW) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNNW is NOT affiliated in any manner with MarketBuzz Reports, or any company mentioned herein.  The commentary, views and opinions expressed in this release by MarketBuzz Reports and are solely those of the MarketBuzz Reports & and are not shared by and do not reflect in any manner the views or opinions of FNNW. The companies that are discussed herein may or may not have approved the statements made in this release.  FNNW is not liable for any investment decisions by its readers or subscribers FNNW and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNNW was not compensated by any public company mentioned herein to disseminate this press release.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNNW undertakes no obligation to update such statements.

FNNW Contact Information:
Company: FN Newswire
Contact email:
U.S. Phone: +1(954)345-0611

SOURCE FN Media Group, LLC

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.